GHAM
XBI icon

Gilman Hill Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Gilman Hill Asset Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,250
Closed -$203K – 230
2024
Q4 		$203K Buy
+2,250
New +$218K 0.04% 208

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Gilman Hill Asset Management's XBI Position: Q1 2025 in Review

Gilman Hill Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2025, closing a stake of 2,250 shares — an estimated $203K sold.

Gilman Hill Asset Management first reported a position in XBI in Q4 2024 and held it in 1 quarter. The position peaked at $203K in Q4 2024. 682 funds tracked by Wall St. Rank hold XBI as of Q1 2025.

  • Gilman Hill Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2025 after selling out during the quarter.
  • Gilman Hill Asset Management sold 2,250 State Street SPDR S&P Biotech ETF shares in Q1 2025, an estimated $203K.
  • Gilman Hill Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and held it in 1 quarter.
  • Gilman Hill Asset Management's State Street SPDR S&P Biotech ETF position peaked at $203K in Q4 2024.
  • 682 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2025.

Based on Gilman Hill Asset Management's 13F filing for Q1 2025, filed 10 Apr 2025.